This list is an analysis based on recent market events. It's not an investment recommendation.
About
Health Technology
Biotechnology
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Employees
82
Country
United States
ISIN
US68236R1032
Listings
0 Comments
Share your thoughts
FAQ
What is Oncorus stock price today?▼
The current price of ONCR is $0.13 USD — it has decreased by -3.08% in the past 24 hours. Watch Oncorus stock price performance more closely on the chart.
What is Oncorus stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oncorus stocks are traded under the ticker ONCR.
What is Oncorus market cap?▼
Today Oncorus has the market capitalization of 3.27M
What is Oncorus revenue for the last year?▼
Oncorus revenue for the last year amounts to 0 USD.
What is Oncorus net income for the last year?▼
ONCR net income for the last year is -77.42M USD.
How many employees does Oncorus have?▼
As of April 22, 2026, the company has 82 employees.